What is Prothena?
Headquartered in Dublin, Ireland, and established in 2012, Prothena is dedicated to the discovery and development of transformative treatments for neurological conditions. The company's focus on neuroscience positions it within a critical and rapidly evolving sector of the pharmaceutical industry. This strategic financing is expected to fuel its ongoing clinical trials and research initiatives, aiming to address unmet medical needs in areas such as Alzheimer's disease and Parkinson's disease.
How much funding has Prothena raised?
Prothena has raised a total of $122.1M across 1 funding round:
Stock Offering
$122.1M
Stock Issuance/Offering (2012): $122.1M, investors not publicly disclosed
What's next for Prothena?
With this substantial backing, Prothena is poised to accelerate its development pipeline and advance its therapeutic candidates through critical clinical stages. The recent strategic investment signals strong confidence from stakeholders in Prothena's scientific approach and its potential to bring groundbreaking therapies to patients. Future developments will likely focus on clinical trial readouts and potential regulatory milestones, further solidifying its position in the competitive neuroscience landscape.
See full Prothena company page
